Litcius/Paper detail

A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies

Anna Solastie, Camilla Virta, Anu Haveri, Nina Ekström, Anu Kantele, Simo Miettinen, Johanna Lempainen, Pinja Jalkanen, Laura Kakkola, Timothée Dub, Ilkka Julkunen, Merit Melin

2021Microbiology Spectrum26 citationsDOIOpen Access PDF

Abstract

SARS-CoV-2 serological assays with excellent clinical performance are essential for reliable estimation of the persistence of immunity after infection or vaccination. In this paper we present a thoroughly validated SARS-CoV-2 serological assay with excellent clinical performance and good comparability to neutralizing antibody titers. Neutralization tests are still considered the gold standard for SARS-CoV-2 serological assays, but our assay can identify samples with neutralizing antibodies with 100% sensitivity and 96% specificity without the need for laborious and slow biosafety level 3 (BSL-3) facility-requiring analyses.

Topics & Concepts

ImmunoassayMultiplexSerologyAntibodyConcordanceVirologyImmunologyPopulationMedicineTiterAntibody titerBiologyMolecular biologyImmunoglobulin GAssay sensitivityNeutralizing antibodyImmunoglobulin MSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchAdvanced Biosensing Techniques and Applications
A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies | Litcius